Cargando…
Biomarkers in Alzheimer's Disease: A Review
Alzheimer's disease is the most common form of dementia affecting millions of individuals worldwide. It is currently diagnosed only via clinical assessments and confirmed by postmortem brain pathology. The development of validated biomarkers for Alzheimer's disease is essential to improve...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395245/ https://www.ncbi.nlm.nih.gov/pubmed/22811931 http://dx.doi.org/10.5402/2012/984786 |
_version_ | 1782237956110548992 |
---|---|
author | Chintamaneni, Meena Bhaskar, Manju |
author_facet | Chintamaneni, Meena Bhaskar, Manju |
author_sort | Chintamaneni, Meena |
collection | PubMed |
description | Alzheimer's disease is the most common form of dementia affecting millions of individuals worldwide. It is currently diagnosed only via clinical assessments and confirmed by postmortem brain pathology. The development of validated biomarkers for Alzheimer's disease is essential to improve diagnosis and accelerate the development of new therapies. Biochemical and neuroimaging markers could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment (MCI), and be used to monitor efficacies of disease-modifying therapies. Cerebrospinal fluid (CSF) levels of Aβ40, Aβ42, total tau, and phosphorylated tau have diagnostic values in AD. Measurements of the above CSF markers in combination are useful in predicting the risk of progression from MCI to AD. New potential biomarkers are emerging, and CSF or plasma marker profiles may eventually become part of the clinician's toolkit for accurate AD diagnosis and management. These biomarkers along with clinical assessment, neuropsychological testing, and neuroimaging could achieve a much higher diagnostic accuracy for AD and related disorders in the future. |
format | Online Article Text |
id | pubmed-3395245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | International Scholarly Research Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-33952452012-07-18 Biomarkers in Alzheimer's Disease: A Review Chintamaneni, Meena Bhaskar, Manju ISRN Pharmacol Review Article Alzheimer's disease is the most common form of dementia affecting millions of individuals worldwide. It is currently diagnosed only via clinical assessments and confirmed by postmortem brain pathology. The development of validated biomarkers for Alzheimer's disease is essential to improve diagnosis and accelerate the development of new therapies. Biochemical and neuroimaging markers could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment (MCI), and be used to monitor efficacies of disease-modifying therapies. Cerebrospinal fluid (CSF) levels of Aβ40, Aβ42, total tau, and phosphorylated tau have diagnostic values in AD. Measurements of the above CSF markers in combination are useful in predicting the risk of progression from MCI to AD. New potential biomarkers are emerging, and CSF or plasma marker profiles may eventually become part of the clinician's toolkit for accurate AD diagnosis and management. These biomarkers along with clinical assessment, neuropsychological testing, and neuroimaging could achieve a much higher diagnostic accuracy for AD and related disorders in the future. International Scholarly Research Network 2012-06-28 /pmc/articles/PMC3395245/ /pubmed/22811931 http://dx.doi.org/10.5402/2012/984786 Text en Copyright © 2012 M. Chintamaneni and M. Bhaskar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Chintamaneni, Meena Bhaskar, Manju Biomarkers in Alzheimer's Disease: A Review |
title | Biomarkers in Alzheimer's Disease: A Review |
title_full | Biomarkers in Alzheimer's Disease: A Review |
title_fullStr | Biomarkers in Alzheimer's Disease: A Review |
title_full_unstemmed | Biomarkers in Alzheimer's Disease: A Review |
title_short | Biomarkers in Alzheimer's Disease: A Review |
title_sort | biomarkers in alzheimer's disease: a review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395245/ https://www.ncbi.nlm.nih.gov/pubmed/22811931 http://dx.doi.org/10.5402/2012/984786 |
work_keys_str_mv | AT chintamanenimeena biomarkersinalzheimersdiseaseareview AT bhaskarmanju biomarkersinalzheimersdiseaseareview |